Ingenol Mebutate Gel (Picato): Key Insights On Uses & Risks
Comprehensive guide to Picato gel for actinic keratosis treatment, usage, side effects, and current status.
Ingenol mebutate gel, marketed as Picato, is a topical treatment specifically indicated for the cutaneous management of non-hyperkeratotic, non-hypertrophic actinic keratosis (also known as solar keratosis) in adults.
Actinic keratosis represents precancerous skin lesions caused by prolonged sun exposure, commonly appearing on sun-damaged areas like the face, scalp, trunk, or extremities. Picato works by inducing rapid cell death in abnormal keratinocytes through a dual mechanism: direct necrosis and a localized inflammatory response that recruits immunocompetent cells, effectively clearing lesions.
Importantly, ingenol mebutate will no longer be prescribed by doctors in the UK and EU due to post-marketing reports of rare skin cancers (like basal cell carcinoma and squamous cell carcinoma) occurring within treatment areas weeks to months after use. Patients who have previously used Picato are advised to monitor their skin regularly for any changes and consult a healthcare provider if suspicious lesions appear.
About ingenol mebutate gel
Ingenol mebutate, derived from the sap of the Euphorbia peplus plant, is formulated as a clear, colorless gel available in two strengths: 0.015% (150 mcg/g) for face and scalp, and 0.05% (500 mcg/g) for trunk and extremities.[10]
The gel is applied topically to a contiguous area of up to 25 cm² (approximately 5 cm x 5 cm) using a single-unit dose tube. It is not systemically absorbed, minimizing broader risks, though local skin reactions are expected and intentional.
Clinical trials demonstrated superior efficacy over vehicle gel. In phase 3 studies, complete clearance rates at day 57 were significantly higher with Picato: 61% vs. 49% for face/scalp (0.015%) and similar benefits for trunk/extremities (0.05%). Long-term follow-up (12 months) showed sustained clearance in 31-44% of completely cleared patients.
| Treatment Area | Strength | Complete Clearance (Picato) | Complete Clearance (Vehicle) |
|---|---|---|---|
| Face/Scalp | 0.015% | 61% | 49% |
| Trunk/Extremities | 0.05% | 44% | 19% |
Patient satisfaction was also higher with Picato, as measured by the Treatment Satisfaction Questionnaire for Medication (TSQM), with statistically significant improvements in global satisfaction scores (p<0.001).
Before using ingenol mebutate gel
To ensure safe use, consult your doctor if any of the following apply:
- You are pregnant or breastfeeding. Limited data exists; use only if benefits outweigh risks.
- You have a history of hypersensitivity to ingenol mebutate or any gel components. Contraindicated in such cases.
- You are immunocompromised. Data is lacking, but local risks may be heightened.
- You have unusual pigmentation, scarring, or prior skin reactions in the treatment area.
- You are using other topical treatments or medications that could interact with the application site.
No dose adjustments are needed for elderly patients, as pharmacokinetics are similar across ages. Inform your doctor of all medications, including over-the-counter and herbal products.
How to use ingenol mebutate gel
Follow these precise instructions for optimal results and safety:
- Prepare the area: On treatment days, wash the area with mild soap and water, then dry thoroughly. Avoid washing treated skin for 6 hours post-application.
- Select strength: Use 0.015% gel for face/scalp (once daily for 3 consecutive days); 0.05% for trunk/extremities (once daily for 2 consecutive days). Do not use 0.05% on face/scalp—it is too strong.
- Apply gel: Open a new single-use tube just before use. Squeeze entire contents onto a fingertip and spread evenly over the 25 cm² contiguous area containing 4-8 lesions. Do not exceed one tube per area per day.
- Dry and avoid contact: Allow to dry for 15 minutes. Wash hands thoroughly after application. Avoid transfer to eyes, mouth, mucosa, or healthy skin. If accidental exposure occurs (e.g., eyes), flush with water and seek medical help.
- Post-application care: Do not cover unless directed. Expect redness, swelling, and peeling—these confirm the gel is working. Symptoms peak around day 4-7 and resolve within 2-4 weeks.
Treatment is prescription-only. Quantity limits often apply: e.g., 3 tubes/90 days for face/scalp or 2 tubes/90 days for trunk/extremities.
Health risks while using ingenol mebutate gel
Local skin responses are common (affecting >90% of users) and resolve without intervention:
- Face/Scalp (0.015%, 3 days): Erythema (94%), exfoliation (85%), scab (80%), swelling (79%), pustules (43%), vesicles (13%).
- Trunk/Extremities (0.05%, 2 days): Erythema (92%), exfoliation (90%), scab (74%), swelling (64%), pustules (23%), vesicles (20%).
Severe reactions (e.g., erosion, bullous dermatitis) occur in ~6-8%; most are mild-moderate. Rare risks include hypersensitivity (e.g., Stevens-Johnson syndrome), scarring, pigmentation changes, herpes zoster activation, or application-site skin cancers (post-authorization findings).
Headaches affect up to 1 in 10 users; manage with analgesics. Eye exposure can cause chemical conjunctivitis or corneal burns—immediate flushing is critical.
Can ingenol mebutate gel cause problems?
Yes, but most are transient local reactions signaling efficacy: redness, itching, pain, flaking, scaling, crusting, swelling, vesiculation, pustulation, erosion.
- Common (>1/10): Application site reactions, headache.
- Uncommon (1/100-1/10): Eye irritation if transferred.
- Rare (<1/1000): Allergic contact dermatitis, hypersensitivity, scarring, pigmentation changes, skin neoplasms.
If reactions are severe, infected (pus, fever), or persist beyond 4 weeks, contact your doctor immediately. Discontinuation occurred in ~1% of trial patients due to reactions. No systemic absorption means low risk for driving/machinery or addiction.
How to store ingenol mebutate gel
Store at room temperature (15-30°C), away from heat, moisture, and children. Discard unused single-use tubes—do not save remnants. Check expiry; do not use if past date.
Frequently Asked Questions (FAQs)
Q: Why was Picato discontinued in the UK and EU?
A: Due to post-marketing reports of skin cancers (e.g., basal/squamous cell carcinoma) in treated areas, observed weeks to months post-use. Regulatory bodies suspended authorization.
Q: What if I experience severe skin reactions?
A: Mild-moderate reactions are expected and resolve in 2-4 weeks. For severe pain, infection signs, or non-healing areas, seek medical advice promptly.
Q: Can I use Picato on sensitive areas like near eyes or mouth?
A: No—avoid periocular, mucosal, or perioral areas. Flush eyes immediately if exposed and get medical care.
Q: Is retreatment possible?
A: Patients not cleared at day 57 or with recurrence could benefit from a second course, per trials, but consult your doctor.
Q: Does Picato work for everyone?
A: Clearance rates: ~44-61% complete at 8 weeks; 31-44% sustained at 12 months in responders. Superior to vehicle.
References
- Picato (ingenol mebutate) Quantity Limit Criteria Program Summary — Blue Cross Blue Shield of Alabama. 2023. https://providers.bcbsal.org/portal/documents/10226/299839/Picato+(ingenol+mebutate)%20Quantity+Limit+Criteria+Program+Summary/c54b2028-5230-409d-9da0-d9627f208d10?version=1.1
- Picato EPAR Product Information — European Medicines Agency (EMA). 2023-10-18. https://www.ema.europa.eu/en/documents/product-information/picato-epar-product-information_en.pdf
- Picato gel 0.05% – NPS MedicineWise — NPS MedicineWise (Australian Government). 2024. https://www.nps.org.au/medicine-finder/picato-gel-0-05
- Ingenol mebutate gel – Picato — Patient.info. 2024. https://patient.info/medicine/ingenol-mebutate-gel-picato
- PICATO (ingenol mebutate) gel Labeling — U.S. Food and Drug Administration (FDA). 2020-07-15. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202833s012lbl.pdf
- Ingenol Mebutate (Picato) Correct Use and Adverse Reactions — Medsafe (New Zealand Ministry of Health). 2015-12. https://medsafe.govt.nz/profs/PUArticles/December2015/IngenolMebutate.htm
- Picato Patient Information Leaflet — Medicines.org.uk (UK MHRA). 2019. https://www.medicines.org.uk/emc/files/pil.2888.pdf
Similar Articles
Read full bio of Sneha Tete
